MMEDV — Minimed Income Statement
0.000.00%
Last trade - 00:00- $5.06bn
- $4.86bn
- $3.10bn
Annual income statement for Minimed, fiscal year end - April 24th, USD millions except per share, conversion factor applied.
2023 April 28th | 2024 April 26th | 2025 April 25th | 2026 April 24th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 2,245 | 2,469 | 2,715 | 3,102 |
| Cost of Revenue | ||||
| Gross Profit | 1,308 | 1,437 | — | 1,680 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 2,314 | 2,538 | 2,861 | 3,292 |
| Operating Profit | -69 | -69 | -146 | -190 |
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -76 | -70 | -147 | -189 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -92 | -108 | -199 | -317 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -97 | -113 | -214 | -333 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -96 | -112 | -213 | -333 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.219 | -0.327 | -0.263 | -0.816 |